French Industry Attacks Price Cut & Drug Shortage Plans
Leem says new stock obligations would add “a new level of complexity”
The French government’s plans for more price cuts and new obligations on manufacturers to avert drug shortages will add another layer of complexity to an already complicated operating environment, says the industry.
You may also be interested in...
A ban on the parallel exporting of medicines from Belgium did not achieve the desired objective of preventing drug shortages, and was also against EU rules, the Constitutional Court has ruled.
Leem says “Inconsistent and unpredictable” policies are hitting industry’s competitiveness and limiting patients’ access to new medicines.
In meta-analyses of biosimilar switching studies, FDA researchers found “zero difference in the risk of death, serious adverse events, and treatment discontinuations between participants who switched between biosimilars and reference products and participants who did not switch.”